Charles M. Farber
University of Texas MD Anderson Cancer Center
66 Papers
436 Citations
Charles M. Farber is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 19, co-authored 57 publications. Previous affiliations of Charles M. Farber include New York University & Memorial Hospital of South Bend.
Chat about Author
Papers
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo,Michelle Byrtek,Keith L Dawson,Xiaolei Zhou,Charles M. Farber,Christopher R. Flowers,John D. Hainsworth,Matthew J. Maurer,James R. Cerhan,Brian K. Link,Andrew D. Zelenetz,Jonathan W. Friedberg,Jonathan W. Friedberg +12 more
TL;DR: In patients with FL who received first-line R-CHOP, POD within 2 years after diagnosis was associated with poor outcomes and should be further validated as a standard end point of chemoimmunotherapy trials of untreated FL.
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan,Mark C. Lanasa,Charles M. Farber,Manjari Pandey,Maria Whelden,Susan J. Faas,Terrie L Ulery,Anjli Kukreja,Lan Li,Camille L. Bedrosian,Xiaoping Zhang,Leonard T. Heffner +11 more
TL;DR: Preliminary positive results support further development of samalizumab as an immune checkpoint inhibitor in chronic lymphocytic leukemia and multiple myeloma and a good safety profile and treatment was associated with reduced tumor burden in a majority of patients with advanced CLL.
Glutathione depletion in chronic lymphocytic leukemia B lymphocytes
Robert Silber,Charles M. Farber,Esperanza B. Papadopoulos,Denise Nevrla,Leonard Liebes,Michael Bruck,Richard Brown,Zoe Nakos Canellakis +7 more
TL;DR: GSH depletion of CLL B lymphocytes may be related to the greater therapeutic efficacy of CLB in B-CLL than in T-C LL, and contributes to the decrease in GSH in B -CLL lymphocytes.
55
A spectrophotometric assay for dehydroascorbate reductase.
TL;DR: A simple spectrophotometric assay for dehydroascorbate reductase based on the change in absorbance associated with the formation of ascorbic acid is described, which correlated well with that obtained by a high-performance liquid chromatography method.
42
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Irene M. Ghobrial,Ashraf Badros,James J. Vredenburgh,Jeffrey Matous,Aaron M. Caola,Alexandra Savell,Patrick Henrick,Claudia E. Paba-Prada,Robert L. Schlossman,Jacob P. Laubach,Jacalyn Rosenblatt,Andrew Yee,Jeffrey S. Wisch,Charles M. Farber,Rodrigo O. Maegawa,Saad Z. Usmani,Joseph Cappuccio,Bradley Rivotto,Kimberly Noonan,Kaitlen Reyes,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson +22 more
TL;DR: The combination of ixazomib, lenalidomide, and dexamethasone is an effective and well-tolerated intervention in high-risk smoldering myeloma and is promising in this patient population at high risk of progression to symptomatic disease.
40